NCT00137111View on ClinicalTrials.gov

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

PHASE3CompletedINTERVENTIONAL

Enrollment

501

Participants

Timeline

Start Date

July 8, 2000

Primary Completion Date

November 30, 2010

Study Completion Date

April 30, 2014

Conditions

Lymphoblastic Leukemia, Acute

Interventions

DRUG

Prednisone, Dexamethasone, Vincristine, Daunorubicin

See Detailed Description sections for details on treatment interventions.

DRUG

Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase

See Detailed Description sections for details on treatment interventions.

DRUG

Methotrexate, Cyclophosphamide, Cytarabine, Etoposide

See Detailed Description sections for details on treatment interventions.

DRUG

Mercaptopurine, Imatinib

See Detailed Description sections for details on treatment interventions.

PROCEDURE

chemotherapy, intrathecal chemotherapy

See Detailed Description sections for details on treatment interventions.

PROCEDURE

steroid therapy, hematopoietic stem cell transplantation

See Detailed Description sections for details on treatment interventions.

Trial Locations (2)

38105

St Jude Children's Research Hospital, Memphis

76104

Cook Children's Medical Center, Fort Worth

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

St. Jude Children's Research Hospital

OTHER

NCT00137111 - Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter